HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thakur, M. L. Articles by Kalinowski, E. A. Search for Related Content PubMed PubMed Citation Articles by Thakur, M. L. Articles by Kalinowski, E. A.

^99mTc-Labeled Vasoactive Intestinal Peptide Analog for Rapid Localization of Tumors in Humans

Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania
Departments of Radiology, Nuclear Medicine, and Pharmacy, Harbor-UCLA Medical Center, Torrance, California

Correspondence: For correspondence or reprints contact: Mathew L. Thakur, PhD, Thomas Jefferson University Hospital, 1020 Locust St., Ste. 359 JAH, Philadelphia, PA 19107.

ABSTRACT

In recent years, imaging tumors with receptor-specific biomolecules has been the focus of increasing interest. Vasoactive intestinal peptide (VIP) has a high affinity for specific receptors that are expressed in high density on a large number of malignant tumors. VIP was modified (TP 3654) without compromising its biologic activity and labeled with ^99mTc. Pharmacokinetics and feasibility studies were performed in 3 healthy volunteers and 11 patients with a history of cancer. Imaging was performed for up to 2 h after injection. Within 24 h after injection of ^99mTc-TP 3654 (370–555 MBq/5 µg), approximately 70% of the tracer cleared through the kidneys and 20% through the liver. Blood clearance was rapid. No adverse reaction was noted in any subject. All known tumors were clearly delineated within 20 mm. Findings were compared with the results of ^99mTc-methoxyisobutyl isonitrile, CT, MRI, or histology. There was concordance in 9 patients. In the other 2 patients, only the VIP scan was positive for tumors known to express VIP receptors. The early results of imaging tumors with ^99mTc-VIP are promising and warrant further study.

Key Words: ^99mTc-VIP • receptor-specific tumor imaging • imaging human tumors with ^99mTc-VIP • vasoactive intestinal peptide

This article has been cited by other articles:

				K. Zhang, M. R. Aruva, N. Shanthly, C. A. Cardi, S. Rattan, C. Patel, C. Kim, P. A. McCue, E. Wickstrom, and M. L. Thakur PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer J. Nucl. Med., January 1, 2008; 49(1): 112 - 121. [Abstract] [Full Text] [PDF]

				G. Mariani, P. A. Erba, and A. Signore Receptor-Mediated Tumor Targeting with Radiolabeled Peptides: There Is More to It than Somatostatin Analogs J. Nucl. Med., December 1, 2006; 47(12): 1904 - 1907. [Full Text] [PDF]

				M. R. Aruva, J. Daviau, S. S. Sharma, and M. L. Thakur Imaging Thromboembolism with Fibrin-Avid 99mTc-Peptide: Evaluation in Swine J. Nucl. Med., January 1, 2006; 47(1): 155 - 162. [Abstract] [Full Text] [PDF]

				X. Tian, M. R. Aruva, W. Qin, W. Zhu, K. T. Duffy, E. R. Sauter, M. L. Thakur, and E. Wickstrom External Imaging of CCND1 Cancer Gene Activity in Experimental Human Breast Cancer Xenografts with 99mTc-Peptide-Peptide Nucleic Acid-Peptide Chimeras J. Nucl. Med., December 1, 2004; 45(12): 2070 - 2082. [Abstract] [Full Text] [PDF]

				M. L. Thakur, M. R. Aruva, J. Gariepy, P. Acton, S. Rattan, S. Prasad, E. Wickstrom, and A. Alavi PET Imaging of Oncogene Overexpression Using 64Cu-Vasoactive Intestinal Peptide (VIP) Analog: Comparison with 99mTc-VIP Analog J. Nucl. Med., August 1, 2004; 45(8): 1381 - 1389. [Abstract] [Full Text] [PDF]

				J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]